Dupilumab dose spacing after initial successful treatment or adverse events in adult patients with atopic dermatitis: A retrospective analysis-Reference-Cited by-同舟云学术

Dupilumab dose spacing after initial successful treatment or adverse events in adult patients with atopic dermatitis: A retrospective analysis

Published:2022-10-21 Issue:12 Volume:35 Page:
ISSN:1396-0296
Container-title:Dermatologic Therapy
language:en
Short-container-title:Dermatologic Therapy

Author:

Patruno Cataldo¹,Potestio Luca²^ORCID,Fabbrocini Gabriella²^ORCID,Napolitano Maddalena³^ORCID

Affiliation:

1. Department of Health Sciences University Magna Graecia of Catanzaro Catanzaro Italy

2. Section of Dermatology ‐ Department of Clinical Medicine and Surgery University of Naples Federico II Naples Italy

3. Department of Medicine and Health Sciences Vincenzo Tiberio University of Molise Campobasso Italy

Publisher

Hindawi Limited

Subject

Dermatology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dth.15933

Reference9 articles.

1. DupixentSummary of Product Characteristics.https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_it.pdf.

2. Long‐term effectiveness of dupilumab up to 52 weeks in atopic dermatitis in 253 adult patients

3. Longer Dupilumab dosing intervals in adult patients with atopic dermatitis: experience from a French multicentre retrospective cohort study [published online ahead of print, 2022 Apr 28];Jendoubi F;Br J Dermatol,2022

4. Patient‐centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis

5. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. [Translated article] RF-Longer Dupilumab Dosing Intervals in Atopic Dermatitis: Optimization or Therapeutic Failure?;Actas Dermo-Sifiliográficas;2024-09

2. FR-Espaciamiento de la dosis de dupilumab en dermatitis atópica: ¿optimización o fracaso terapéutico?;Actas Dermo-Sifiliográficas;2024-09

3. Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis;JAMA Dermatology;2024-08-07

4. Stepping down biologics in asthma: is it time to challenge the status quo?;European Respiratory Journal;2024-08

5. Therapeutic Modulation of Dupilumab in Patients with Severe Atopic Dermatitis: Clinical Effectiveness in Real Life;Dermatitis®;2024-07-22